,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2023', 'fs': 'Feb 2023', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSw5G2AT'}, 'Id': 'a0POZ00000FSw5G2AT', 'Event_Date__c': '2023-02-13', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Feb 2023', 'Status_History__c': 'a132P000000EDPTQA4'}, 'change': None}]",Feb 2023,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that widening access for rituximab to include induction phase therapy to manage active lupus nephritis class III and IV be <strong>declined</strong>.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee noted that inadequately managed lupus nephritis class III and IV can increase the risk of progression of the disease and end-stage kidney disease. The Committee noted the unmet health need due to individuals being unable to be appropriately managed on the current available therapies. The Committee noted that there was no evidence that individuals would experience improved health outcomes if they received rituximab as part of the induction therapy and rituximab would not address the unmet health need of these individuals.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that widening access for rituximab to include induction phase therapy to manage active lupus nephritis class III and IV be <strong>declined</strong>.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee noted that inadequately managed lupus nephritis class III and IV can increase the risk of progression of the disease and end-stage kidney disease. The Committee noted the unmet health need due to individuals being unable to be appropriately managed on the current available therapies. The Committee noted that there was no evidence that individuals would experience improved health outcomes if they received rituximab as part of the induction therapy and rituximab would not address the unmet health need of these individuals.</p>', 'change': None}, 'Published_Discussion': {'s': '<h3><em style=""font-size: 14px;"">Māori impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee discussed the impact of funding rituximab for the induction phase for the treatment of active lupus nephritis class III or IV on Māori health areas of focus and Māori health outcomes. The Committee noted that Māori are disproportionally affected by lupus nephritis class III and IV; Māori are less likely to be appropriately managed on current therapeutic regimens due to practical healthcare barriers, and Māori experience higher rates of end stage renal disease and mortality compared to non-Māori, non-Pacific people (<a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al.\xa0Lupus. 2022; 31: 1671-1678</a>).</p><h3><em style=""font-size: 14px;"">Health need</em></h3><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that lupus nephritis is a severe complication of systemic lupus erythematosus which occurs when the immune system inadvertently attacks the kidneys, leading to inflammation and organ damage if not adequately managed. The Committee noted that lupus nephritis can harm the ability of the kidneys to properly remove waste from blood, control the body’s fluid status, regulate hormone production, and salt availability required for managing blood pressure and blood volume.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that renal involvement occurs in up to 50% of individuals with systemic lupus erythematosus during the disease course and has been estimated to lead to end-stage kidney disease in about 10% of individuals. The Committee noted there are several classes of lupus nephritis which are identified on renal biopsy.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that current steroid and immunosuppressant therapies can have intolerable side effects negatively impacting an individual’s general health, mental wellbeing and fertility and these adverse effects could lead to discontinuation of the treatment.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that progressive and unmanaged lupus nephritis increases the risk of end-stage renal disease and the individual requiring renal replacement therapies such as dialysis and renal transplantation. The Committee noted lupus nephritis is associated with severe comorbidities such as infections, cardiovascular complications, and increased risk of malignancy.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that progression of lupus nephritis, end stage kidney disease and experiencing comorbidities relating to their condition can impact an individual’s ability to perform daily tasks, affect the individual’s quality of life and survival and renal replacement therapies pose significant cost to the healthcare system.\xa0</p><p class=""ql-indent-1"">1.6.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the number of individuals with lupus nephritis class III and IV in New Zealand was unknown. The study by <a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al</a> (2022) estimated that there may be 10-25 new individuals per year diagnosed with lupus nephritis class III or IV in New Zealand who may require treatment. The Committee noted that not all individuals with lupus nephritis had a renal biopsy unless class III or IV was suspected.</p><p class=""ql-indent-1"">1.6.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted an observational study of children diagnosed with biopsy proven lupus nephritis seen by Kidz First paediatric rheumatology and/or Starship renal services between 1992 and January 2018 (<a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al.\xa0Lupus. 2022; 31: 1671-1678</a>).\xa0The Committee noted that in this study there were 42 individuals diagnosed with childhood onset lupus nephritis, 67% were Māori or Pacific people and there was an estimated annual incidence rate of 0.01 per 100,000 people. The Committee noted that, on average, childhood onset lupus nephritis was diagnosed at age 11.9 years.</p><p class=""ql-indent-1"">1.6.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that <a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al</a> (2022) found that Māori and Pacific people are disproportionally affected by lupus nephritis class III and IV, and they are also less likely to be appropriately managed on current therapeutic regimens due to practical healthcare barriers, institutional racism, discrimination and devaluation of spiritual and cultural practices\xa0and experience higher rates of end stage kidney disease and mortality in comparison to non-Māori, non-Pacific people (<a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al.\xa0Lupus. 2022; 31: 1671-1678</a>).</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the current <a href=""https://kdigo.org/wp-content/uploads/2023/03/KDIGO-2023-Lupus-Nephritis-Guideline_Public-Review_9-Mar-2023.pdf"" target=""_blank"">Kidney Disease: Improving Global Outcomes:\xa0guidelines</a> (KDIGO) for the management of active lupus nephritis class III and IV:</p><p class=""ql-indent-1"">1.7.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Individuals with active lupus nephritis class III or IV without membranous component should be treated initially with glucocorticoids and either low dose cyclophosphamide or mycophenolic acid analogues.</p><p class=""ql-indent-1"">1.7.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>A regimen of reduced-dose glucocorticoids following a short course of methylprednisolone pulses may be considered during the initial treatment of active lupus nephritis when both the kidney and extra-renal disease manifestations show satisfactory improvement.</p><p class=""ql-indent-1"">1.7.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Intravenous cyclophosphamide should be used as the initial therapy for active Class III and Class IV lupus nephritis in patients who may have difficulty adhering to an oral regimen.</p><p class=""ql-indent-1"">1.7.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>A mycophenolic acid analogues-based regimen is the preferred initial therapy of proliferative lupus nephritis for patients at high risk of infertility, patients who have a moderate to high prior cyclophosphamide exposure.</p><p class=""ql-indent-1"">1.7.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Triple therapy with glucocorticoids, low dose mycophenolic acid analogues and a calcineurin inhibitor (cyclosporine or tacrolimus) should be reserved for patients who cannot tolerate full dose mycophenolic analogues or cyclophosphamide regimes.</p><p class=""ql-indent-1"">1.7.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In individuals with eGFR of at least 45mL/min per 1.73m3 voclosporin can be added to the mycophenolic acid analogues and glucocorticoids regimen as initial therapy for 1-year.</p><p class=""ql-indent-1"">1.7.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>There is an emerging role for B-lymphocyte targeting biologics in the treatment of lupus nephritis class III and IV and Belimumab can be added to standard therapy.</p><p class=""ql-indent-1"">1.7.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Rituximab may be considered for patients with persistent disease activity or repeat flares.</p><p class=""ql-indent-1"">1.7.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Other therapies, such as azathioprine or leflunomide combined with glucocorticoids, may be considered in lieu of the recommended initial drugs for proliferative lupus nephritis in situations of patient intolerance, lack of availability, and/or excessive cost of standard drugs, but these alternatives may be associated with inferior efficacy, including increased rate of disease flares and/or increased incidence of drug toxicities.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the current special authority for Rituximab for the treatment refractory systemic lupus erythematosus. The Committee noted that rituximab is available for individuals with relapsed/refractory systemic lupus erythematosus with an immediate and severe threat of death or organ failure which includes severe lupus nephritis.\xa0The Committee considered that determining whether the disease is refractory to standardised treatments can be difficult and noted that there are no factors that can reliably predict and identify a subgroup of patients likely to be inadequately managed with standardised treatment.</p><h3><em style=""font-size: 14px;"">Health benefit</em></h3><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted evidence from two relevant randomised controlled studies, the EXPLORER study (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548300/"" target=""_blank"">Merrill et al. Arthritis Rheum. 2010; 62: 222–233</a>) and the LUNAR study (<a href=""https://pubmed.ncbi.nlm.nih.gov/22231479/"" target=""_blank"">Rovin et al. Arthritis Rheum. 2012; 64:1215-26</a>).\xa0</p><p class=""ql-indent-1"">1.9.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The EXPLORER trial, which involved 257 patients who had moderate to severe active systemic lupus erythematosus assessed by the British Isles Lupus Assessment scale (BILAG). Patients were randomised 2:1 to receive 1000mg rituximab or placebo on days 1, 15, 168, and 182 in addition to prednisone (0.5-1mg/kg tapered to 10mg over 10 weeks) and background immunosuppressant therapy. The study reported no significant differences between rituximab and placebo on primary and secondary endpoints in the study.</p><p class=""ql-indent-1"">1.9.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The LUNAR study was a randomised controlled study in 144 patients with class III or class IV lupus nephritis treated concomitantly with mycophenolate and corticosteroids. Patients were randomized 1:1 to receive rituximab (1000 mg) or placebo on days 1, 15, 168, and 182 both in combination with prednisone 0.75 mg/kg tapered to 10 mg over 10 weeks. The primary endpoint measured the renal response status, irrespective of individuals experiencing flares of symptoms following 52 weeks of the therapeutic regimen. Overall, there was no significant differences in the complete or partial renal response status between rituximab and placebo groups.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the strength and quality of the evidence for the use of rituximab in the induction phase of therapy for lupus nephritis class III or IV to be weak. The Committee noted that rituximab demonstrated no efficacious benefit when used as an add on to standard level of care when treating individuals with lupus nephritis. The Committee noted rituximab is not recommended in the current KDIGO guidelines in the induction phase of treating class III-IV lupus nephritis.</p><h3><em style=""font-size: 14px;"">Suitability </em></h3><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that rituximab is an infusion-based therapy and would require nursing and infusion resource. The Committee noted that not all individuals would have access to an appropriate infusion setting.</p><h3><em style=""font-size: 14px;"">Cost and Savings</em></h3><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for rituximab if it were to be funded in New Zealand to be used during the induction phase of therapy to manage lupus nephritis class III and IV.\xa0This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff. <span style=""color: black;"">\xa0</span></p><p><br></p><p><span style=""color: black;""><span class=""ql-cursor"">\ufeff</span></span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000FSw5H&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ0000004kc9"" alt=""image.png""></img></p>', 'fs': '<h3><em style=""font-size: 14px;"">Māori impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee discussed the impact of funding rituximab for the induction phase for the treatment of active lupus nephritis class III or IV on Māori health areas of focus and Māori health outcomes. The Committee noted that Māori are disproportionally affected by lupus nephritis class III and IV; Māori are less likely to be appropriately managed on current therapeutic regimens due to practical healthcare barriers, and Māori experience higher rates of end stage renal disease and mortality compared to non-Māori, non-Pacific people (<a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al.\xa0Lupus. 2022; 31: 1671-1678</a>).</p><h3><em style=""font-size: 14px;"">Health need</em></h3><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that lupus nephritis is a severe complication of systemic lupus erythematosus which occurs when the immune system inadvertently attacks the kidneys, leading to inflammation and organ damage if not adequately managed. The Committee noted that lupus nephritis can harm the ability of the kidneys to properly remove waste from blood, control the body’s fluid status, regulate hormone production, and salt availability required for managing blood pressure and blood volume.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that renal involvement occurs in up to 50% of individuals with systemic lupus erythematosus during the disease course and has been estimated to lead to end-stage kidney disease in about 10% of individuals. The Committee noted there are several classes of lupus nephritis which are identified on renal biopsy.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that current steroid and immunosuppressant therapies can have intolerable side effects negatively impacting an individual’s general health, mental wellbeing and fertility and these adverse effects could lead to discontinuation of the treatment.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that progressive and unmanaged lupus nephritis increases the risk of end-stage renal disease and the individual requiring renal replacement therapies such as dialysis and renal transplantation. The Committee noted lupus nephritis is associated with severe comorbidities such as infections, cardiovascular complications, and increased risk of malignancy.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that progression of lupus nephritis, end stage kidney disease and experiencing comorbidities relating to their condition can impact an individual’s ability to perform daily tasks, affect the individual’s quality of life and survival and renal replacement therapies pose significant cost to the healthcare system.\xa0</p><p class=""ql-indent-1"">1.6.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the number of individuals with lupus nephritis class III and IV in New Zealand was unknown. The study by <a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al</a> (2022) estimated that there may be 10-25 new individuals per year diagnosed with lupus nephritis class III or IV in New Zealand who may require treatment. The Committee noted that not all individuals with lupus nephritis had a renal biopsy unless class III or IV was suspected.</p><p class=""ql-indent-1"">1.6.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted an observational study of children diagnosed with biopsy proven lupus nephritis seen by Kidz First paediatric rheumatology and/or Starship renal services between 1992 and January 2018 (<a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al.\xa0Lupus. 2022; 31: 1671-1678</a>).\xa0The Committee noted that in this study there were 42 individuals diagnosed with childhood onset lupus nephritis, 67% were Māori or Pacific people and there was an estimated annual incidence rate of 0.01 per 100,000 people. The Committee noted that, on average, childhood onset lupus nephritis was diagnosed at age 11.9 years.</p><p class=""ql-indent-1"">1.6.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that <a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al</a> (2022) found that Māori and Pacific people are disproportionally affected by lupus nephritis class III and IV, and they are also less likely to be appropriately managed on current therapeutic regimens due to practical healthcare barriers, institutional racism, discrimination and devaluation of spiritual and cultural practices\xa0and experience higher rates of end stage kidney disease and mortality in comparison to non-Māori, non-Pacific people (<a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al.\xa0Lupus. 2022; 31: 1671-1678</a>).</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the current <a href=""https://kdigo.org/wp-content/uploads/2023/03/KDIGO-2023-Lupus-Nephritis-Guideline_Public-Review_9-Mar-2023.pdf"" target=""_blank"">Kidney Disease: Improving Global Outcomes:\xa0guidelines</a> (KDIGO) for the management of active lupus nephritis class III and IV:</p><p class=""ql-indent-1"">1.7.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Individuals with active lupus nephritis class III or IV without membranous component should be treated initially with glucocorticoids and either low dose cyclophosphamide or mycophenolic acid analogues.</p><p class=""ql-indent-1"">1.7.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>A regimen of reduced-dose glucocorticoids following a short course of methylprednisolone pulses may be considered during the initial treatment of active lupus nephritis when both the kidney and extra-renal disease manifestations show satisfactory improvement.</p><p class=""ql-indent-1"">1.7.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Intravenous cyclophosphamide should be used as the initial therapy for active Class III and Class IV lupus nephritis in patients who may have difficulty adhering to an oral regimen.</p><p class=""ql-indent-1"">1.7.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>A mycophenolic acid analogues-based regimen is the preferred initial therapy of proliferative lupus nephritis for patients at high risk of infertility, patients who have a moderate to high prior cyclophosphamide exposure.</p><p class=""ql-indent-1"">1.7.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Triple therapy with glucocorticoids, low dose mycophenolic acid analogues and a calcineurin inhibitor (cyclosporine or tacrolimus) should be reserved for patients who cannot tolerate full dose mycophenolic analogues or cyclophosphamide regimes.</p><p class=""ql-indent-1"">1.7.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In individuals with eGFR of at least 45mL/min per 1.73m3 voclosporin can be added to the mycophenolic acid analogues and glucocorticoids regimen as initial therapy for 1-year.</p><p class=""ql-indent-1"">1.7.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>There is an emerging role for B-lymphocyte targeting biologics in the treatment of lupus nephritis class III and IV and Belimumab can be added to standard therapy.</p><p class=""ql-indent-1"">1.7.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Rituximab may be considered for patients with persistent disease activity or repeat flares.</p><p class=""ql-indent-1"">1.7.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Other therapies, such as azathioprine or leflunomide combined with glucocorticoids, may be considered in lieu of the recommended initial drugs for proliferative lupus nephritis in situations of patient intolerance, lack of availability, and/or excessive cost of standard drugs, but these alternatives may be associated with inferior efficacy, including increased rate of disease flares and/or increased incidence of drug toxicities.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the current special authority for Rituximab for the treatment refractory systemic lupus erythematosus. The Committee noted that rituximab is available for individuals with relapsed/refractory systemic lupus erythematosus with an immediate and severe threat of death or organ failure which includes severe lupus nephritis.\xa0The Committee considered that determining whether the disease is refractory to standardised treatments can be difficult and noted that there are no factors that can reliably predict and identify a subgroup of patients likely to be inadequately managed with standardised treatment.</p><h3><em style=""font-size: 14px;"">Health benefit</em></h3><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted evidence from two relevant randomised controlled studies, the EXPLORER study (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548300/"" target=""_blank"">Merrill et al. Arthritis Rheum. 2010; 62: 222–233</a>) and the LUNAR study (<a href=""https://pubmed.ncbi.nlm.nih.gov/22231479/"" target=""_blank"">Rovin et al. Arthritis Rheum. 2012; 64:1215-26</a>).\xa0</p><p class=""ql-indent-1"">1.9.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The EXPLORER trial, which involved 257 patients who had moderate to severe active systemic lupus erythematosus assessed by the British Isles Lupus Assessment scale (BILAG). Patients were randomised 2:1 to receive 1000mg rituximab or placebo on days 1, 15, 168, and 182 in addition to prednisone (0.5-1mg/kg tapered to 10mg over 10 weeks) and background immunosuppressant therapy. The study reported no significant differences between rituximab and placebo on primary and secondary endpoints in the study.</p><p class=""ql-indent-1"">1.9.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The LUNAR study was a randomised controlled study in 144 patients with class III or class IV lupus nephritis treated concomitantly with mycophenolate and corticosteroids. Patients were randomized 1:1 to receive rituximab (1000 mg) or placebo on days 1, 15, 168, and 182 both in combination with prednisone 0.75 mg/kg tapered to 10 mg over 10 weeks. The primary endpoint measured the renal response status, irrespective of individuals experiencing flares of symptoms following 52 weeks of the therapeutic regimen. Overall, there was no significant differences in the complete or partial renal response status between rituximab and placebo groups.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the strength and quality of the evidence for the use of rituximab in the induction phase of therapy for lupus nephritis class III or IV to be weak. The Committee noted that rituximab demonstrated no efficacious benefit when used as an add on to standard level of care when treating individuals with lupus nephritis. The Committee noted rituximab is not recommended in the current KDIGO guidelines in the induction phase of treating class III-IV lupus nephritis.</p><h3><em style=""font-size: 14px;"">Suitability </em></h3><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that rituximab is an infusion-based therapy and would require nursing and infusion resource. The Committee noted that not all individuals would have access to an appropriate infusion setting.</p><h3><em style=""font-size: 14px;"">Cost and Savings</em></h3><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for rituximab if it were to be funded in New Zealand to be used during the induction phase of therapy to manage lupus nephritis class III and IV.\xa0This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff. <span style=""color: black;"">\xa0</span></p><p><br></p><p><span style=""color: black;""><span class=""ql-cursor"">\ufeff</span></span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000FSw5H&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ0000004kc9"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for [application] in the treatment of Lupus Nephritis class III or IV for induction therapy</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for [application] in the treatment of Lupus Nephritis class III or IV for induction therapy</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2023', 'fs': 'Mar 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Nephrology Advisory Committee at meeting Friday 17 March 2023.', 'fs': 'Clinical advice received from Nephrology Advisory Committee at meeting Friday 17 March 2023.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSw5H2AT'}, 'Id': 'a0POZ00000FSw5H2AT', 'Event_Date__c': '2023-03-17', 'Event_Description__c': 'Clinical advice received from Nephrology Advisory Committee at meeting Friday 17 March 2023.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Mar 2023', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that widening access for rituximab to include induction phase therapy to manage active lupus nephritis class III and IV be <strong>declined</strong>.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee noted that inadequately managed lupus nephritis class III and IV can increase the risk of progression of the disease and end-stage kidney disease. The Committee noted the unmet health need due to individuals being unable to be appropriately managed on the current available therapies. The Committee noted that there was no evidence that individuals would experience improved health outcomes if they received rituximab as part of the induction therapy and rituximab would not address the unmet health need of these individuals.</p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for [application] in the treatment of Lupus Nephritis class III or IV for induction therapy</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<h3><em style=""font-size: 14px;"">Māori impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee discussed the impact of funding rituximab for the induction phase for the treatment of active lupus nephritis class III or IV on Māori health areas of focus and Māori health outcomes. The Committee noted that Māori are disproportionally affected by lupus nephritis class III and IV; Māori are less likely to be appropriately managed on current therapeutic regimens due to practical healthcare barriers, and Māori experience higher rates of end stage renal disease and mortality compared to non-Māori, non-Pacific people (<a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al.\xa0Lupus. 2022; 31: 1671-1678</a>).</p><h3><em style=""font-size: 14px;"">Health need</em></h3><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that lupus nephritis is a severe complication of systemic lupus erythematosus which occurs when the immune system inadvertently attacks the kidneys, leading to inflammation and organ damage if not adequately managed. The Committee noted that lupus nephritis can harm the ability of the kidneys to properly remove waste from blood, control the body’s fluid status, regulate hormone production, and salt availability required for managing blood pressure and blood volume.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that renal involvement occurs in up to 50% of individuals with systemic lupus erythematosus during the disease course and has been estimated to lead to end-stage kidney disease in about 10% of individuals. The Committee noted there are several classes of lupus nephritis which are identified on renal biopsy.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that current steroid and immunosuppressant therapies can have intolerable side effects negatively impacting an individual’s general health, mental wellbeing and fertility and these adverse effects could lead to discontinuation of the treatment.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that progressive and unmanaged lupus nephritis increases the risk of end-stage renal disease and the individual requiring renal replacement therapies such as dialysis and renal transplantation. The Committee noted lupus nephritis is associated with severe comorbidities such as infections, cardiovascular complications, and increased risk of malignancy.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that progression of lupus nephritis, end stage kidney disease and experiencing comorbidities relating to their condition can impact an individual’s ability to perform daily tasks, affect the individual’s quality of life and survival and renal replacement therapies pose significant cost to the healthcare system.\xa0</p><p class=""ql-indent-1"">1.6.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the number of individuals with lupus nephritis class III and IV in New Zealand was unknown. The study by <a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al</a> (2022) estimated that there may be 10-25 new individuals per year diagnosed with lupus nephritis class III or IV in New Zealand who may require treatment. The Committee noted that not all individuals with lupus nephritis had a renal biopsy unless class III or IV was suspected.</p><p class=""ql-indent-1"">1.6.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted an observational study of children diagnosed with biopsy proven lupus nephritis seen by Kidz First paediatric rheumatology and/or Starship renal services between 1992 and January 2018 (<a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al.\xa0Lupus. 2022; 31: 1671-1678</a>).\xa0The Committee noted that in this study there were 42 individuals diagnosed with childhood onset lupus nephritis, 67% were Māori or Pacific people and there was an estimated annual incidence rate of 0.01 per 100,000 people. The Committee noted that, on average, childhood onset lupus nephritis was diagnosed at age 11.9 years.</p><p class=""ql-indent-1"">1.6.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that <a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al</a> (2022) found that Māori and Pacific people are disproportionally affected by lupus nephritis class III and IV, and they are also less likely to be appropriately managed on current therapeutic regimens due to practical healthcare barriers, institutional racism, discrimination and devaluation of spiritual and cultural practices\xa0and experience higher rates of end stage kidney disease and mortality in comparison to non-Māori, non-Pacific people (<a href=""https://pubmed.ncbi.nlm.nih.gov/36168149/#:~:text=Conclusion%3A%20Lupus%20nephritis%20is%20more,developing%20rapid%20histologic%20disease%20progression."" target=""_blank"">Concannon et al.\xa0Lupus. 2022; 31: 1671-1678</a>).</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the current <a href=""https://kdigo.org/wp-content/uploads/2023/03/KDIGO-2023-Lupus-Nephritis-Guideline_Public-Review_9-Mar-2023.pdf"" target=""_blank"">Kidney Disease: Improving Global Outcomes:\xa0guidelines</a> (KDIGO) for the management of active lupus nephritis class III and IV:</p><p class=""ql-indent-1"">1.7.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Individuals with active lupus nephritis class III or IV without membranous component should be treated initially with glucocorticoids and either low dose cyclophosphamide or mycophenolic acid analogues.</p><p class=""ql-indent-1"">1.7.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>A regimen of reduced-dose glucocorticoids following a short course of methylprednisolone pulses may be considered during the initial treatment of active lupus nephritis when both the kidney and extra-renal disease manifestations show satisfactory improvement.</p><p class=""ql-indent-1"">1.7.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Intravenous cyclophosphamide should be used as the initial therapy for active Class III and Class IV lupus nephritis in patients who may have difficulty adhering to an oral regimen.</p><p class=""ql-indent-1"">1.7.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>A mycophenolic acid analogues-based regimen is the preferred initial therapy of proliferative lupus nephritis for patients at high risk of infertility, patients who have a moderate to high prior cyclophosphamide exposure.</p><p class=""ql-indent-1"">1.7.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Triple therapy with glucocorticoids, low dose mycophenolic acid analogues and a calcineurin inhibitor (cyclosporine or tacrolimus) should be reserved for patients who cannot tolerate full dose mycophenolic analogues or cyclophosphamide regimes.</p><p class=""ql-indent-1"">1.7.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In individuals with eGFR of at least 45mL/min per 1.73m3 voclosporin can be added to the mycophenolic acid analogues and glucocorticoids regimen as initial therapy for 1-year.</p><p class=""ql-indent-1"">1.7.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>There is an emerging role for B-lymphocyte targeting biologics in the treatment of lupus nephritis class III and IV and Belimumab can be added to standard therapy.</p><p class=""ql-indent-1"">1.7.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Rituximab may be considered for patients with persistent disease activity or repeat flares.</p><p class=""ql-indent-1"">1.7.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Other therapies, such as azathioprine or leflunomide combined with glucocorticoids, may be considered in lieu of the recommended initial drugs for proliferative lupus nephritis in situations of patient intolerance, lack of availability, and/or excessive cost of standard drugs, but these alternatives may be associated with inferior efficacy, including increased rate of disease flares and/or increased incidence of drug toxicities.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the current special authority for Rituximab for the treatment refractory systemic lupus erythematosus. The Committee noted that rituximab is available for individuals with relapsed/refractory systemic lupus erythematosus with an immediate and severe threat of death or organ failure which includes severe lupus nephritis.\xa0The Committee considered that determining whether the disease is refractory to standardised treatments can be difficult and noted that there are no factors that can reliably predict and identify a subgroup of patients likely to be inadequately managed with standardised treatment.</p><h3><em style=""font-size: 14px;"">Health benefit</em></h3><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted evidence from two relevant randomised controlled studies, the EXPLORER study (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548300/"" target=""_blank"">Merrill et al. Arthritis Rheum. 2010; 62: 222–233</a>) and the LUNAR study (<a href=""https://pubmed.ncbi.nlm.nih.gov/22231479/"" target=""_blank"">Rovin et al. Arthritis Rheum. 2012; 64:1215-26</a>).\xa0</p><p class=""ql-indent-1"">1.9.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The EXPLORER trial, which involved 257 patients who had moderate to severe active systemic lupus erythematosus assessed by the British Isles Lupus Assessment scale (BILAG). Patients were randomised 2:1 to receive 1000mg rituximab or placebo on days 1, 15, 168, and 182 in addition to prednisone (0.5-1mg/kg tapered to 10mg over 10 weeks) and background immunosuppressant therapy. The study reported no significant differences between rituximab and placebo on primary and secondary endpoints in the study.</p><p class=""ql-indent-1"">1.9.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The LUNAR study was a randomised controlled study in 144 patients with class III or class IV lupus nephritis treated concomitantly with mycophenolate and corticosteroids. Patients were randomized 1:1 to receive rituximab (1000 mg) or placebo on days 1, 15, 168, and 182 both in combination with prednisone 0.75 mg/kg tapered to 10 mg over 10 weeks. The primary endpoint measured the renal response status, irrespective of individuals experiencing flares of symptoms following 52 weeks of the therapeutic regimen. Overall, there was no significant differences in the complete or partial renal response status between rituximab and placebo groups.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the strength and quality of the evidence for the use of rituximab in the induction phase of therapy for lupus nephritis class III or IV to be weak. The Committee noted that rituximab demonstrated no efficacious benefit when used as an add on to standard level of care when treating individuals with lupus nephritis. The Committee noted rituximab is not recommended in the current KDIGO guidelines in the induction phase of treating class III-IV lupus nephritis.</p><h3><em style=""font-size: 14px;"">Suitability </em></h3><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that rituximab is an infusion-based therapy and would require nursing and infusion resource. The Committee noted that not all individuals would have access to an appropriate infusion setting.</p><h3><em style=""font-size: 14px;"">Cost and Savings</em></h3><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for rituximab if it were to be funded in New Zealand to be used during the induction phase of therapy to manage lupus nephritis class III and IV.\xa0This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff. <span style=""color: black;"">\xa0</span></p><p><br></p><p><span style=""color: black;""><span class=""ql-cursor"">\ufeff</span></span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000FSw5H&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ0000004kc9"" alt=""image.png""></img></p>', 'Status_History__c': 'a13OZ000001up4FYAQ'}, 'change': None}]",Mar 2023,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSw5I2AT'}, 'Id': 'a0POZ00000FSw5I2AT', 'Event_Date__c': '2023-09-06', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a13OZ000001tQJ7YAM'}, 'change': None}]",Sep 2023,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSw5J2AT'}, 'Id': 'a0POZ00000FSw5J2AT', 'Event_Date__c': '2023-09-08', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a13OZ000001vnvdYAA'}, 'change': None}]",Sep 2023,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2024', 'fs': 'Oct 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSw5K2AT'}, 'Id': 'a0POZ00000FSw5K2AT', 'Event_Date__c': '2024-10-17', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'Formatted_Date__c': 'Oct 2024', 'Status_History__c': 'a13OZ00000FTVcWYAX'}, 'change': None}]",Oct 2024,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2024', 'fs': 'Nov 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSw5L2AT'}, 'Id': 'a0POZ00000FSw5L2AT', 'Event_Date__c': '2024-11-30', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Nov 2024', 'Status_History__c': 'a13OZ00000HCm7BYAT'}, 'change': None}]",Nov 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
